Congratulations to the Nanoscope Therapeutics Inc. team including Samarendra Mohanty,PhD, Subrata Batabyal, PhD, Ananta Laxmi Ayyagari Ph.D and Naj Sharif, PhD, DSC, on their just-published research article in The Journal of Gene Medicine (https://lnkd.in/ggwpPwid) . The article (https://lnkd.in/gAtFiZT6) details how research aimed to determine the ocular and systemic safety of MCO-010 in adult Beagle dogs following intravitreal (IVT) injection. In the study, MCO-010 demonstrated a favorable safety profile when administered to the eyes of adult Beagle dogs. This study established the No Observed Adverse Effect Level for MCO-010 and guided selection of doses for human clinical trials. Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. 100-week data from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772) was recently presented by Dr. Michael Singer at ASRS – American Society of Retina Specialists Meeting in Stockholm. The company has also completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126 ). MCO-010 has received FDA fast-track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophies secondary to AMD. For more information about Nanoscope Therapeutics, visit our website: nanostherapeutics.com #Genetherapy #retinitispigmentosa #stargardt # geographic atrophy #optogenetics
Nanoscope Therapeutics Inc.
Biotechnology Research
Dallas, Texas 5,605 followers
Bringing Back the Light of Hope
About us
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa
- Website
-
http://www.nanostherapeutics.com/
External link for Nanoscope Therapeutics Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Dallas, Texas
- Type
- Privately Held
- Founded
- 2017
Locations
-
Primary
2777 N Stemmons Fwy
Dallas, Texas 75207, US
Employees at Nanoscope Therapeutics Inc.
Updates
-
The Nanoscope Therapeutics Inc. team was excited to be in Stockholm last week for the ASRS – American Society of Retina Specialists Annual Scientific Meeting where Dr. Michael Singer presented for the first time 100 week top-line results end-of-study data from RESTORE, a randomized controlled trial of Nanoscope's MCO optogenetic gene therapy in patients with severe vision loss related to Retinitis Pigmentosa (RP). It was a great opportunity to interact with others who are devoted to finding impactful treatments for those suffering from degenerative retinal diseases. For more information about the development status of MCO-010 visit our website: nanostherapeutics.com #optogenetics #genetherapy #retina #retinitispigmentosa
-
-
Join bioscience industry members in North Texas including Nanoscope Therapeutics Inc.'s Khandan Baradaran, SVP of Quality and Regulatory for an informative BioNTX panel discussion on Wednesday, July 17th. #dallas #texas #biotech https://lnkd.in/gFf8EevC
Innovation and the bioscience industry are flourishing in North Texas. Our Facilities Advisory Committee invites you to join BioNTX at the Texas Research Quarter on July 17th from 3:00pm – 6:00pm, hosted by NexPoint. Join us for an insightful discussion on Building a Robust Life Science Ecosystem: The Bridge Between Research, Clinical Trials, & Manufacturing. This event will focus on enhancing North Texas's already impressive clinical trial ecosystem through collaboration of clinical scale manufacturing, research organizations, and patient care. Our expert panel will provide valuable perspectives on the future of clinical trials and explore strategies for advancing life-saving treatments. EVENT DETAILS Date/Time - Wednesday, July 17th - Event Check-In: 3:00 pm - Program Begins: 3:30 pm - (Networking reception and property tours to follow) Location - Texas Research Quarter - 5400 Legacy Drive, Plano, TX 75024 - (Entrance on Parkwood Blvd) Register now https://lnkd.in/eZXWHr58 #clinicaltrials #biotech #biomanufacturing #bioscience #lifescience #medtech #clinicaltrial #biotechnology #facilities #NorthTexas #lifesciences #innovation #research #patientcare
-
-
Nanoscope Therapeutics Inc. reposted this
We're thrilled to introduce Sulagna Bhattacharya, Co-Founder and CEO of Nanoscope Therapeutics Inc., as one of our panelists at HealthCon 2024. A positive tech disruptor, Sulagna's innovative work is making significant strides in the biotech industry. Join us to gain insights from her experience and visionary approach, shaping the future of health technology. Don’t miss this chance to hear from one of the leading voices in therapeutic advancements! RSVP to HealthCon 2024 now at https://rb.gy/he4lbw. Thank you to our sponsors: Children's Health, Civitas Capital Group, AlixPartners, BTRNSFRMD, Hancock Whitney, UNT at Frisco, Dallas Fort Worth International Airport (DFW), Coca-Cola Southwest Beverages.
-
-
The Nanoscope Therapeutics Inc. Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in a presentation by Dr. Michael Singer, Clinical Professor of Ophthalmology at the University of Texas Health Science Center, at the 2024 ASRS – American Society of Retina Specialists Annual Scientific Meeting taking place from July 17-July 20, 2024 in Stockholm, Sweden. Dr. Singer will present end-of-study data from RESTORE, a randomized controlled trial of Nanoscope's MCO optogenetic gene therapy in patients with severe vision loss related to Retinitis Pigmentosa (RP). MCO-treated subjects from RESTORE experienced clinically meaningful improvements in best-corrected visual acuity (BCVA) in a statistically significant manner. Dr. Singer will discuss the importance and magnitude of the vision restoration observed in MCO-treated patients from RESTORE in the context of the natural history of declining vision in this patient population. Details for the presentation are as follows: Abstract Title: BCVA analysis of low- or high-dose MCO-010 mutation agnostic optogenetic therapy for retinitis pigmentosa: FIRST TIME 100-week TOPLINE Results from a Phase 2b/3 Randomized Sham-Controlled Clinical Trial (RESTORE) Session Type: Late-Breaking Symposium Presentation Session Title: Symposium 3: Hereditary Retinal Disease & Genetics Session Date: Friday, July 19th Session Time: 9:17am CEST Presenter: Dr. Michael Singer, Clinical Professor of Ophthalmology at the University of Texas Health Science Center For more information: nanostherapeutics.com #retinitispigmentosa #ASRS2024 #genetherapy #optogenetics https://lnkd.in/g8B74FmT
-
Nanoscope Therapeutics Inc. reposted this
Thank you D Magazine for including Nanoscope Therapeutics Inc. CEO Sulagna Bhattacharya in your feature on female entrepreneurs making a splash in the Dallas/Fort Worth area. We are proud to see her included in such outstanding company. #dallas #fortworth #womenleaders #entrepreneurs https://lnkd.in/gyshDZgu
Meet Three Game-Changing DFW Entrepreneurs
https://www.dmagazine.com
-
Thank you D Magazine for including Nanoscope Therapeutics Inc. CEO Sulagna Bhattacharya in your feature on female entrepreneurs making a splash in the Dallas/Fort Worth area. We are proud to see her included in such outstanding company. #dallas #fortworth #womenleaders #entrepreneurs https://lnkd.in/gyshDZgu
Meet Three Game-Changing DFW Entrepreneurs
https://www.dmagazine.com
-
Members of the Nanoscope Therapeutics Inc. leadership team will participate in one-on-one meetings with investors at the 2024 Leerink Partners Biopharma Private Company Connect, being held virtually on June 25-26, 2024. Participating will be CEO & Co-Founder Sulagna Bhattacharya, President & Co-Founder Samarendra Mohanty, Chief Medical Officer Samuel B Barone, MD, CFO Michael Marquez and VP Strategy & Business Development Jared Stephens. Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently announced the 100-week data from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126 ). MCO-010 has received FDA fast-track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophies secondary to AMD. For more information visit nanostherapeutics.com #biotechnology #ophthalmology #genetherapy https://lnkd.in/gJkhm4d3
Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect - Nanoscope Therapeutics
https://nanostherapeutics.com